Cancer Immunotherapy: The Global Market is Expected to Grow at a CAGR of 13.8% from 2018 to Reach $152.83 Billion by 2024
DUBLIN, Nov. 9, 2018 /PRNewswire/ --
The "Cancer Immunotherapy Market By Type (Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy), Application (Lung, Breast, Multiple Myeloma, Colorectal, Melanoma, Prostate), And End User- Global Forecast To 2024" report has been added to ResearchAndMarkets.com's offering.
The global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to reach USD 152.83 billion by 2024.
The high growth of cancer immunotherapy market is attributed to factors such as rising incidence of cancer globally, rising adoption of cancer immunotherapies over other conventional cancer treatments owing to the increased survival rate and less side effects with immunotherapy drugs, increasing number of ongoing clinical trials with the help of rising investments by major players in the market, and development of bioinformatics tools that are enhancing the drug development process for cancer immunotherapy market.
However, the high cost of the cancer immunotherapy treatment is restricting the growth of this market to some extent. Apart from this, growing R&D investments by major players in the market to develop cancer immunotherapies and high growth prospects in the developing countries such as China and India provides significant opportunity in this market.
Monoclonal antibodies dominated the global cancer immunotherapy market, mainly due to their high adoption for cancer treatment, rising number of US FDA approvals, and better five-year survival rates as compared to other cancer treatment options available in the market.
Cancer immunotherapy market for lung cancer application commanded the largest share, mainly attributed to increasing incidence of lung cancer, the significant benefit of cancer immunotherapy for lung cancer compared with other treatment options, and rising adoption of immunotherapies in lung cancer owing to the higher survival rate.
North America commanded the largest share of the global cancer immunotherapy market in 2017, followed by Europe and the Asia Pacific region. The large share of this region is mainly attributed to the factors such as rising incidence of cancer globally, growing adoption of immunotherapy for cancer treatment, rising investments in collaboration and mergers, and enhancement in the drug development process owing to the development of bioinformatics.
Furthermore, the regulatory bodies such as US FDA and European Commission are specially focusing on the research of cancer immunotherapy due to the advantages of this therapy compared with other treatment options. The faster drug approval in the cancer immunotherapy is also responsible for the growth of this market.
Key Topics Covered
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation
3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Application Segment Analysis
3.5. End User Analysis
3.6. Regional Analysis
3.7. Competitive Analysis
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Rising Cancer Incidence
4.2.2. Growing Adoption of Immunotherapy over other Treatment Options
4.2.3. Increasing Number of Technological Collaborations and Mergers
4.2.4. Development of Bioinformatics Tools Enhancing Drug Development Process
4.3. Market Restraints
4.3.1. High Cost of Treatment
4.4. Market Opportunities
4.4.1. Growing R&D Expenditure
4.4.2. High Growth Prospects in Emerging Economies
4.5. Market Challenges
4.5.1. Limited Funds with Small and Mid-Sized Organizations to Initiate the Clinical Trials
4.5.2. Complexities of Tumor
5. Industry Insights
5.1. Key Industry Trends
5.1.1. Personalized Immunotherapy
5.1.2. Implementation of Next-Generation Sequencing Technologies
5.1.3. Immunotherapy Combination
5.1.4. Accelerated Approval
5.1.5. China's Rapidly Expanding Cancer Immunotherapy Market
5.2. Evolution of Cancer Immunotherapy
5.3. Opdivo and Keytruda: Major Products in Cancer Immunotherapy Market
6. Cancer Immunotherapy Market, by Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Checkpoint Inhibitors
6.4. Immunomodulators
6.5. Vaccines
6.6. Cell Therapies
7. Cancer Immunotherapy Market, by Application
7.1. Introduction
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Prostate Cancer
7.7. Multiple Myeloma
7.8. Other Cancer Types
8. Cancer Immunotherapy Market, by End User
8.1. Overview
8.2. Hospitals
8.3. Clinics and Others
9. Cancer Immunotherapy Market, by Region
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis
10.3. Competitor Benchmarking
10.4. Competitive Situation and Trends
10.4.1. Approvals
10.4.2. Agreements and Collaborations
10.4.3. Acquisitions
10.4.4. Other Developments
11. Company Profiles
11.1. Astrazeneca
11.2. Amgen
11.3. Bristol-Myers Squibb
11.4. Eli Lilly
11.5. Johnson & Johnson
11.6. Merck & Co., Inc.
11.7. Novartis International AG
11.8. Pfizer Inc.
11.9. F. Hoffmann-La Roche
11.10. Celgene Corporation
For more information about this report visit https://www.researchandmarkets.com/research/ksz2vd/cancer?w=5
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article